Frontiers in Immunology (Mar 2023)
Immune checkpoint inhibitor-associated toxicity in advanced non-small cell lung cancer: An updated understanding of risk factors
- Xiangxiao Hu,
- Xiangxiao Hu,
- Xiangxiao Hu,
- Lina Wang,
- Lina Wang,
- Lina Wang,
- Lina Wang,
- Bin Shang,
- Junren Wang,
- Junren Wang,
- Junren Wang,
- Jian Sun,
- Jian Sun,
- Jian Sun,
- Bin Liang,
- Bin Liang,
- Bin Liang,
- Lili Su,
- Lili Su,
- Lili Su,
- Wenjie You,
- Wenjie You,
- Wenjie You,
- Wenjie You,
- Shujuan Jiang,
- Shujuan Jiang,
- Shujuan Jiang
Affiliations
- Xiangxiao Hu
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Xiangxiao Hu
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Xiangxiao Hu
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Lina Wang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Lina Wang
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Lina Wang
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Lina Wang
- Department of Respiratory and Critical Care Medicine, Shanghai Ninth People's Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
- Bin Shang
- Department of Thoracic Surgery, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China
- Junren Wang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Junren Wang
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Junren Wang
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Jian Sun
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Jian Sun
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Jian Sun
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Bin Liang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Bin Liang
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Bin Liang
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Lili Su
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Lili Su
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Lili Su
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Wenjie You
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Wenjie You
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Wenjie You
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- Wenjie You
- Department of Thoracic Surgery, Fudan University Shanghai Cancer Center, Shanghai, China
- Shujuan Jiang
- Department of Respiratory and Critical Care Medicine, Shandong Provincial Hospital affiliated to Shandong First Medical University, Jinan, China
- Shujuan Jiang
- Shandong Key Laboratory of Infectious Respiratory Disease, Jinan, China
- Shujuan Jiang
- Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan, China
- DOI
- https://doi.org/10.3389/fimmu.2023.1094414
- Journal volume & issue
-
Vol. 14
Abstract
Immune checkpoint inhibitors (ICIs), such as programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), cytotoxic T lymphocyte antigen 4 (CTLA-4) antibodies, etc, have revolutionized cancer treatment strategies, including non-small cell lung cancer (NSCLC). While these immunotherapy agents have achieved durable clinical benefits in a subset of NSCLC patients, they bring in a variety of immune-related adverse events (irAEs), which involve cardiac, pulmonary, gastrointestinal, endocrine and dermatologic system damage, ranging from mild to life-threatening. Thus, there is an urgent need to better understand the occurrence of irAEs and predict patients who are susceptible to those toxicities. Herein, we provide a comprehensive review of what is updated about the clinical manifestations, mechanisms, predictive biomarkers and management of ICI-associated toxicity in NSCLC. In addition, this review also provides perspective directions for future research of NSCLC-related irAEs.
Keywords
- non-small cell lung cancer
- immune-related toxicity
- combined immunotherapies
- predictive biomarker
- immune checkpoint inhibitor
